Ovoca Bio PLC
LSE:OVB
Intrinsic Value
Ovoca Bio Plc is a clinical-stage biopharmaceutical company. [ Read More ]
The intrinsic value of one OVB stock under the Base Case scenario is 4.86 GBX. Compared to the current market price of 0.8 GBX, Ovoca Bio PLC is Undervalued by 84%.
Valuation Backtest
Ovoca Bio PLC
Run backtest to discover the historical profit from buying and selling OVB stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Ovoca Bio PLC
Current Assets | 5m |
Cash & Short-Term Investments | 4.4m |
Receivables | 447k |
Other Current Assets | 132k |
Non-Current Assets | 6.4m |
Long-Term Investments | 262k |
PP&E | 21k |
Intangibles | 6.2m |
Other Non-Current Assets | 2k |
Current Liabilities | 2.4m |
Accounts Payable | 1.3m |
Other Current Liabilities | 1.2m |
Non-Current Liabilities | 292k |
Other Non-Current Liabilities | 292k |
Earnings Waterfall
Ovoca Bio PLC
Revenue
|
0
EUR
|
Operating Expenses
|
-2.3m
EUR
|
Operating Income
|
-2.3m
EUR
|
Other Expenses
|
-47k
EUR
|
Net Income
|
-2.3m
EUR
|
Free Cash Flow Analysis
Ovoca Bio PLC
OVB Profitability Score
Profitability Due Diligence
Ovoca Bio PLC's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Ovoca Bio PLC's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
OVB Solvency Score
Solvency Due Diligence
Ovoca Bio PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Ovoca Bio PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OVB Price Targets Summary
Ovoca Bio PLC
Shareholder Return
OVB Price
Ovoca Bio PLC
Average Annual Return | 13.55% |
Standard Deviation of Annual Returns | 68.23% |
Max Drawdown | -98% |
Market Capitalization | 652.5k GBX |
Shares Outstanding | 81 563 806 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ovoca Bio Plc is a clinical-stage biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 5 full-time employees. The firm is engaged in identifying and developing therapeutics targeting the treatment of female sexual dysfunction. The Company’s product BP101 is a synthetic peptide, administered through a nasal spray that is being developed for the treatment of female sexual dysfunction-hypoactive sexual desire disorder (HSDD). The Company’s subsidiaries include Silver Star Ltd, Bulun LLC, Magsel LLC, IVIX LLC and OVB (Australia) Pty Ltd. The firm operates in Ireland, the United Kingdom (UK) and Russia.
Contact
IPO
Employees
Officers
The intrinsic value of one OVB stock under the Base Case scenario is 4.86 GBX.
Compared to the current market price of 0.8 GBX, Ovoca Bio PLC is Undervalued by 84%.